Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating
Recommend 7 Positive 6 Negative 4 |
||||
|
||||
|
According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK) has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK. Meanwhile, HANSOH PHARMA's Hengmeida, which is used for the treatment of candidiasis, has been granted a drug registration certificate by China's National Medical Products Administration. The company's other product development projects are also progressing smoothly. UOB Kay Hian kept a Buy rating on HANSOH PHARMA, with a target price raised to HKD40 from HKD29. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
